PEPTIDE CORTEXThe library
← The library

Kisspeptin

research/clinical researchSexual Health
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeReproductive axis
MechanismStimulates GnRH → LH/FSH release
EffectsStimulates GnRH → LH/FSH release
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published3 sourced
Clinical trialKisspeptin-10 in healthy men (George, JCEM 2011)
RouteIntravenous bolus and infusion
FrequencySingle bolus or infusion
StartingIV bolus: maximal LH rise at 1 mcg/kg (3 mcg/kg gave a smaller response)
EscalationNone
TargetInfusions at 1.5 and 4 mcg/kg/h raised LH
Clinical trialKisspeptin-54 IVF trigger (Abbara 2015)
RouteSubcutaneous
FrequencySingle dose
StartingArms: 3.2, 6.4, 9.6 or 12.8 nmol/kg
EscalationNone
TargetHighest pregnancy rates at 9.6 nmol/kg

Women at high OHSS risk. No kisspeptin product is approved.

Community protocol — not clinically establishedCommunity guide (kisspeptin-10)
RouteSubcutaneous
Frequency1-2x daily
StartingLow-dose pulse 50-100 mcg SC
EscalationStandard pulse 100-200 mcg; or 100 mcg twice daily
Target50-200 mcg 1-2x daily
CycleShort 2-4 weeks on / 2-4 off; standard 4-6 weeks on / 4 off

The guide warns continuous exposure desensitises the LH response.

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not routine; endocrine effects; clinician supervision

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.